Skip to search formSkip to main contentSkip to account menu

casopitant

A centrally-acting neurokinin 1 (NK1) receptor antagonist with antidepressant and antiemetic activities. Casopitant competitively binds to and blocks… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

AntiemeticsNeurokinin-1 Receptor AntagonistsPiperazinesPiperidines

Narrower (1)

GW679769
casopitant mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Why No Casopitant-only Arm?
Review
2009
Review
2009
FDA Pipeline preview, August 2009 (trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, velaglucerase alfa)
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and… 
2009
2009
Efficacy of casopitant, a novel neurokinin-1 receptor antagonist, for antiemesis over repeated cycles of moderately emetogenic chemotherapy.
2008
2008
Effect of casopitant, a novel neurokinin -1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of…
20587 Background: In clinical studies, casopitant is a dose- and duration-dependent inhibitor of CYP3A4, as well as a moderate… 
2008
2008
Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized double…
2008
2008
Phase III results for the Novel Neurokinin-1 (NK-1) Receptor Antagonist, Casopitant: Single Oral Dosing Regimen for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients (Pts) Receiving…
2008
2008
Casopitant regimens ease the way for chemotherapy
  • 2008
  • Corpus ID: 195173860
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)